Motilin: endogenous GI prokinetic peptide research overview

Motilin is a 22-amino acid peptide hormone produced and released by endocrine Mo cells (previously called M cells) lining the duodenal and jejunal mucosa. First characterized in the early 1970s, motilin occupies a central role in regulating the migrating motor complex (MMC) — the cyclical pattern of gastrointestinal smooth muscle contractions that sweeps the upper GI tract clean between meals. Its clinical relevance has expanded considerably since the discovery that macrolide antibiotics, including erythromycin and azithromycin, act as motilin receptor agonists, forming the pharmacological basis for their prokinetic use and inspiring an entire class of investigational motilin agonist drugs.

What is motilin?

Motilin is a linear, 22-amino acid peptide (sequence: Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Met-Gln-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln) with a molecular weight of approximately 2,698 Da. It is encoded by the MLN gene on chromosome 13q13.3. The peptide is synthesized as a 114-amino acid prepropeptide and proteolytically processed to the mature 22-residue form prior to secretion.

The existence of a duodenal hormone stimulating gastric motility was first proposed by Brown and colleagues (J.C. Brown, University of British Columbia) in the early 1970s, with the initial isolation and characterization of porcine motilin published by Brown, Mutt, and Dryburgh in 1971 in the Canadian Journal of Biochemistry. The amino acid sequence of human motilin was subsequently determined, and its receptor — the motilin receptor (MLNR), a class A GPCR — was identified and cloned in the 1990s. The receptor is expressed prominently in gastric and intestinal smooth muscle and enteric neurons, as well as in the central nervous system to a lesser extent.

Motilin is secreted in a cyclical, fasting-state pattern with peak plasma concentrations occurring approximately every 90–120 minutes, correlating with phase III MMC contractions. These 'housekeeper' contractions propel undigested residues and bacteria from the stomach and small intestine toward the colon. Motilin release is suppressed by feeding and stimulated by alkalinization of the duodenum, fat, and certain neural signals. Plasma motilin concentrations in humans typically range from 20–200 pmol/L in the fasting state. Itoh and colleagues at Nagoya University contributed foundational work characterizing the cyclical MMC-linked release pattern in humans during the 1980s.

Mechanism of action

Motilin exerts its prokinetic effects through binding to the motilin receptor (MLNR / GPR38), a Gq-coupled class A GPCR. Receptor activation on gastric and intestinal smooth muscle cells triggers the phospholipase C pathway, increasing intracellular inositol triphosphate and diacylglycerol, which mobilizes intracellular calcium from the sarcoplasmic reticulum. The resulting rise in cytosolic calcium activates smooth muscle contraction via calmodulin-dependent myosin light-chain kinase. Simultaneously, motilin receptor activation on enteric neurons triggers acetylcholine release, further amplifying smooth muscle contraction through the cholinergic pathway. The net result is antroduodenal propulsive contractions consistent with phase III MMC activity.

A landmark insight into motilin pharmacology was the discovery that erythromycin — a macrolide antibiotic — acts as a motilin receptor agonist. Published by Itoh and colleagues in 1984 and elaborated in subsequent work, including the influential 1993 PubMed-indexed review by Peeters (PMID 8470625), this observation explained the known prokinetic side effects of erythromycin and launched investigations into macrolide antibiotics as GI motility drugs. Erythromycin binds to the same orthosteric or overlapping site on MLNR as the endogenous peptide, stimulating gastric emptying at subantimicrobial doses. Azithromycin also acts on the motilin receptor and has been evaluated for prokinetic use in conditions such as gastroparesis. A 2023 structural study published in Science Advances (PMC10017046) resolved the cryo-EM structure of MLNR bound to both motilin and erythromycin, revealing overlapping but non-identical binding modes that account for their differing desensitization kinetics.

A key pharmacological challenge is tachyphylaxis: repeated stimulation of the motilin receptor leads to rapid receptor desensitization and downregulation, blunting the sustained prokinetic response with continuous or high-dose administration. This property is observed with erythromycin (particularly at higher doses) and was a design constraint that motivated the development of non-macrolide motilin receptor agonists with improved pharmacokinetic and desensitization profiles.

What the research shows

The research landscape around motilin agonism has been dominated by attempts to develop drugs for gastroparesis — delayed gastric emptying associated with diabetes, post-surgical states, and idiopathic causes. Because erythromycin's prokinetic effect is established but limited by tachyphylaxis and antibiotic side effects, pharmaceutical interest focused on novel, selective non-macrolide motilin receptor agonists. Several compounds reached clinical development. Camicinal (GSK-962040), a small-molecule, orally bioavailable motilin receptor agonist developed by GlaxoSmithKline, demonstrated accelerated gastric emptying in phase 2 studies in patients with type-1 diabetes and gastroparesis, with a more favorable tachyphylaxis profile than erythromycin. However, GSK discontinued development before completing phase 3 trials, citing strategic portfolio decisions and incomplete efficacy data. Mitemcinal (GM-611), a macrolide-derived motilin agonist, also showed prokinetic activity in clinical trials but was discontinued.

Ulimorelin, sometimes cited in the motilin agonist context, is actually a ghrelin receptor (GHS-R1a) agonist rather than a motilin receptor agonist. While ghrelin and motilin pathways both influence GI motility — and the ghrelin receptor shares structural homology with MLNR — ulimorelin did not demonstrate superiority over placebo in its phase 2b trial for gastroparesis; the pathways are pharmacologically distinct. This distinction is important for correctly interpreting the clinical development literature.

Low-dose erythromycin (1–3 mg/kg IV or 250 mg orally) remains in clinical use as a prokinetic in intensive care settings for feeding intolerance and in select gastroparesis patients, supported by multiple randomized trials demonstrating acceleration of gastric emptying. Azithromycin has been evaluated as an alternative with a longer half-life and potentially more sustained effect. A 2023 Science Advances structural study (PMC10017046) used cryo-EM to characterize MLNR-motilin and MLNR-erythromycin complexes, providing molecular-level insight that may inform future drug design efforts. As of 2026, no motilin receptor agonist has achieved regulatory approval for gastroparesis.

Pharmacokinetics of endogenous motilin

Endogenous motilin has a short plasma half-life of approximately 4–5 minutes in humans, consistent with rapid enzymatic degradation by serum and tissue peptidases. Fasting plasma motilin concentrations oscillate between approximately 20 and 200 pmol/L in healthy adults, cycling in synchrony with MMC phases. The peptide is cleared through renal and hepatic routes. Because of its short half-life, exogenous administration of native motilin as a therapeutic agent presents significant practical challenges; most drug development has therefore pursued small-molecule receptor agonists or peptide analogs with improved metabolic stability.

Pharmacokinetic data for exogenous motilin peptide administration in humans are limited to early pharmacodynamic characterizations. Camicinal (the investigational small-molecule agonist) was orally bioavailable with a half-life compatible with once-daily dosing, representing a significant pharmacokinetic improvement over the parent peptide. Motilin itself does not appear in any approved pharmaceutical formulation.

Physiologic levels and pharmacologic dose data

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Endogenous motilin: fasting plasma concentrations in healthy adults range from approximately 20–200 pmol/L (roughly 54–540 pg/mL), cycling with MMC phase. These are physiologic values, not administered doses. For pharmacologic context: intravenous erythromycin administered as a motilin receptor agonist (prokinetic use) has been studied at doses of 1–3 mg/kg IV, with 3 mg/kg IV shown to stimulate gastric emptying in multiple clinical studies. Oral erythromycin at 250 mg three times daily has been used in clinical practice as a prokinetic, though tachyphylaxis limits long-term use. Azithromycin at 250 mg has also been evaluated. Camicinal in phase 2 trials was administered orally at doses up to 200 mg.

Motilin as a pure peptide has no approved therapeutic dosing and no published human dose-finding study as an administered agent. Research-grade motilin peptide is available for in vitro receptor binding and cell-based assay work. Any pharmacologic use of exogenous motilin peptide in humans would be experimental and falls outside established regulatory frameworks.

Storage and handling

Research-grade motilin peptide is typically supplied lyophilized and should be stored at −20 °C, protected from moisture and light. Once reconstituted in an appropriate aqueous buffer, solutions should be aliquoted and stored at −80 °C for long-term stability or at 2–8 °C for short-term use (typically up to 7 days). Repeated freeze-thaw cycles degrade peptide integrity. As a linear 22-amino acid peptide without backbone modifications, motilin is susceptible to proteolytic degradation in solution; strict aseptic technique and appropriate buffer conditions (neutral to slightly acidic pH) are recommended for in vitro work.

What motilin is NOT

Motilin is sometimes conflated with ghrelin because both peptides regulate upper GI motility and share structural receptor homology between MLNR and GHSR. They are distinct: ghrelin is a 28-amino acid acylated peptide (octanoylated at Ser-3) with a different gene locus, different receptor, and broad metabolic and appetite-regulating functions beyond GI motility. Motilin has no known acylation and no established role in appetite regulation, growth hormone secretion, or energy homeostasis. Ulimorelin is a ghrelin receptor agonist, not a motilin receptor agonist, and the two compound classes should not be conflated in interpreting clinical trial data. Motilin is also distinct from secretin, CCK, GIP, and GLP-1, which are separate GI hormones with distinct receptors and biological programs. Finally, motilin should not be confused with motilium (domperidone), a dopamine receptor antagonist with prokinetic properties, nor with metoclopramide — neither acts via the motilin receptor.

References

Key primary sources include: Brown, Mutt & Dryburgh's original motilin isolation (Can J Biochem, 1971); Itoh et al.'s characterization of cyclical motilin-MMC coupling in humans; Peeters' authoritative review of erythromycin as a motilin agonist (PMID 8470625); and the 2023 Science Advances cryo-EM structural study of the motilin receptor bound to motilin and erythromycin (PMC10017046). For camicinal clinical data, see GSK-published phase 2 trial literature. IUPHAR/BPS pharmacology is available at the Guide to Pharmacology motilin receptor entry.